Key facts
- It has raised $43.0M; the latest was Grant ($850K) in Mar 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, Co-Win Ventures, Proxima Ventures (China), 3E Bioventures Capital, AB Magnitude Ventures Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Myrobalan Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Myrobalan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Myrobalan Therapeutics
Operator of a therapeutic biotechnology company intended for developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and central nervous system (CNS) conditions. The company offers neurological processes such as demyelination and neuroinflammation and innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates that are positioned for addressing unmet medical needs in CNS diseases, enabling healthcare professionals to provide therapeutic opportunities for a large patient population with unmet medical needs.
- Sector
- Healthcare
- HQ
- Medford, MA, United States
- Founded
- 2021
- Employees
- 19
- Website
- myrotx.com/
- Ownership
- Privately Held (backing)
Myrobalan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myrobalan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myrobalan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.